This is true. Unsubstantiated pumping can be just as detrimental to retail investors as unsubstantiated shorting. It depends on the circumstances, but my opinion is that it's generally easier to sow fear than it is to instill confidence.
I'm trying to find data on persistent t-cell count after 9 months. I know we touted phase 1 as having persistent t-cell count until 9, but can't find how long it persists for and to what degree. Can anybody give me some direction. Thanks in advance.
To be fair, I think retail investors have a real impact on share price. Perhaps not daily, but IMO many of the big swings are the result of bandwagon buying and panic selling result from swing and day traders. The slow stepping up and down of price is likely controlled by others.
It's seems to me that manage cares less about dilution and more about making sure there is enough money to see us through to commercialization. Money not spent on P3 is just applied directly to the cash runway. Sure, there's an argument that raising money at higher PPS minimizes dilution, but management has largely ignored this principle.
Posting issue. I don't think S3 is necessarily an indication that INO will go it alone. I can easily see a situation where money is raised to gain leverage in a negotiation.
Because he's stated in the past that he likes to raise money when they don't need it. That's part of the reason why we have a cash runway through 2017.
Dumb. This whole red scare business is getting old. I don't care if you're long or short. I'll read any post that has substance. Cameron's posts substance (and as I understand it is long).
Give it a rest. SEC does not monitor "abuse" flags on Yahoo. Yahoo barely monitors "abuse" flags on Yahoo.
People always see the starting of a trial as a catalyst, but I can never remember that being the case. P3 is going to take at least two years. The next catalysts would be interim and final results for VGX-3112 trials. I previously listed partnership on list of next catalysts, but I'm less enthused about that now.
I re-reading the release, I can see your reading of it.
"Inovio will independently advance the clinical programs for VGX-3100, including the phase III study for CIN 2/3, and its broader HPV franchise for associated diseases but will consider partnering opportunities that serve to maximize the long term financial benefit to the Company and its shareholders."
I haven't listened to the call yet and am assuming clarification during the call helped you come to that conclusion.
That's kind of the point. Prior to P2 release, INO was clear that they were open to partnering VGX-3100. Now that they've verbatim stated that they're proceeding independently, it makes me believe that the terms weren't favorable for shareholders, which implicates that big pharma was not convinced with P2 results.
I understand the frustration, but this isn't that surprising. It generally takes at least a year to get a P3 going. This is in line with what I expected. My big disappointment is that they didn't find a partner for VGX-3100.